133.46
price down icon1.08%   -1.46
after-market アフターアワーズ: 133.46
loading
前日終値:
$134.92
開ける:
$134
24時間の取引高:
716.64K
Relative Volume:
0.51
時価総額:
$12.29B
収益:
$2.41B
当期純損益:
$305.80M
株価収益率:
45.24
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
+3.37%
1か月 パフォーマンス:
+7.48%
6か月 パフォーマンス:
-5.28%
1年 パフォーマンス:
-8.90%
1日の値動き範囲:
Value
$132.10
$135.00
1週間の範囲:
Value
$127.03
$135.94
52週間の値動き範囲:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1164)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
1,800
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

NBIX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
133.46 12.29B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
14.75 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
154.96 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.96 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.68 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.40 20.17B 16.54B -1.64B 749.00M -1.45

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Jun 16, 2025

Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting - MSN

Jun 16, 2025
pulisher
Jun 14, 2025

Neurocrine Biosciences’ SWOT analysis: biotech stock balances Ingrezza success with pipeline potential - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com

Jun 12, 2025
pulisher
Jun 11, 2025

Endometriosis Market on Track for Major Expansion by 2034, - openPR.com

Jun 11, 2025
pulisher
Jun 10, 2025

Neurocrine Loses Suit Challenging Hormone Treatment Patent - Law360

Jun 10, 2025
pulisher
Jun 10, 2025

Judge Tosses Neurocrine’s Suit Over Spruce Hormone-Drug Patent - Bloomberg Law News

Jun 10, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences names new Chief Information Officer By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer - The Malaysian Reserve

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences Names Lewis Choi as Chief Information Officer - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Endometriosis Pain Pipeline 2025: Mechanism of Action, Route - openPR.com

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences (NBIX) Appoints Lewis Choi as Chief Information Officer - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

Neurocrine Biosciences names new Chief Information Officer - Investing.com

Jun 09, 2025
pulisher
Jun 05, 2025

Congenital Adrenal Hyperplasia Market Growth Projections - openPR.com

Jun 05, 2025
pulisher
Jun 03, 2025

(NBIX) Technical Data - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Nxera earns $15 million as Neurocrine advances schizophrenia drug - The Pharma Letter

Jun 03, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Projects Strong Ingrezza Sales For 2025 - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 02, 2025

Analyst Expectations For Neurocrine Biosciences's Future - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

RBC Capital Reiterates Outperform Rating for Neurocrine Biosciences (NBIX) | NBIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Announces Phase 4 KINECT-PRO Data - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

[Latest] USA Tardive Dyskinesia Treatment Market: New Drugs, - openPR.com

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine (NBIX) Reports Positive Results from INGREZZA Study on Tardive Dyskinesia | NBIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Groundbreaking INGREZZA Study Reveals Life-Changing Benefits for Tardive Dyskinesia Patients in Just 4 Weeks - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Quantisnow

Jun 01, 2025
pulisher
May 30, 2025

Huntington's Disease Society hosts Team Hope Walk in Tulsa Saturday - KTUL

May 30, 2025
pulisher
May 30, 2025

Director Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - MSN

May 30, 2025
pulisher
May 30, 2025

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III - insights.citeline.com

May 30, 2025
pulisher
May 29, 2025

Neurocrine Biosciences director sells shares worth $1.16 million By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Neurocrine Biosciences director sells shares worth $1.16 million - Investing.com

May 29, 2025
pulisher
May 29, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophr - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff - Endpoints News

May 29, 2025
pulisher
May 29, 2025

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - The Malaysian Reserve

May 29, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK

May 28, 2025
pulisher
May 25, 2025

Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia

May 25, 2025
pulisher
May 24, 2025

How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Cetera Investment Advisers Purchases 2,593 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

May 23, 2025
pulisher
May 20, 2025

Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourette Syndrome Treatment Market Detailed Analysis - openPR.com

May 20, 2025
pulisher
May 17, 2025

Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq

May 16, 2025

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Neurocrine Biosciences Inc (NBIX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
GORMAN KEVIN CHARLES
Director
May 27 '25
Sale
120.38
9,613
1,157,211
514,596
$295.52
price down icon 1.55%
drug_manufacturers_specialty_generic RDY
$14.51
price down icon 1.09%
$9.12
price down icon 1.41%
$14.90
price down icon 0.93%
$16.40
price down icon 0.79%
大文字化:     |  ボリューム (24 時間):